Hoy Wendy, McDonald Stephen P
Centre of Chronic Disease, University of Queensland, Royal Brisbane Hospital, Herston, Australia.
Kidney Int Suppl. 2004 Nov(92):S25-31. doi: 10.1111/j.1523-1755.2004.09207.x.
Australian Aborigines in remote areas are experiencing an epidemic of renal disease, type 2 diabetes, hypertension, and cardiovascular disease. Adult deaths are increased 3- to 6-fold, and renal failure more than 20-fold. Renal disease is marked by albuminuria. We describe its distributions and correlations in two remote communities in the Northern Territory.
Observations in Community 1 included a screen of 939 adult participants (18+ years, 90% recruitment), a treatment program, and 8 to 11 years of follow-up. In Community 2, a screen of 259 people, or 60% of adults, included HbA1c, homocysteine, C-reactive protein (CRP), CMV serology, and carotid intimal media thickness (CIMT). Albumin/creatinine ratio (ACR) was measured by immunoassay in g/mol on random urine, with microalbuminuria defined as 3.4 to 33, and overt albuminuria as ACR 34+.
Dipstick urine protein trace+ correctly classified 76% of people with ACR 3.4+, and dipstick protein 1+ correctly classified 82% of people with ACR 34+. ACR was stable to glucose loading and water diuresis in subsets of people in Community 1. ACR levels rose steeply with age. Rates of micro- and overt albuminuria in Community 1 were 28% and 21%, and in Community B were 31% and 13%. ACR correlated inversely with estimated glomerular filtration rate (GFR). ACR also correlated directly with weight, blood pressure, cholesterol, triglycerides, random glucose, HbA1c, homocysteine, and GGT levels, and inversely with HDL cholesterol. ACR correlated with skin sores, scabies, high titer antibodies to Helicobacter pylori, high-titer CMV antibodies, with CRP over a greatly elevated range and, inversely, with birth weight. Finally, ACR correlated with CIMT. Baseline ACR predicted loss of GFR over time. ACR 3.4+ predicted all-cause and cardiovascular hospitalization, while ACR 34+ predicted all renal failure developing over 11 years and all-cause natural deaths and cardiovascular disease deaths. ACEi treatment for people with ACR 34+ reduced renal failure and natural deaths, but the hierarchical effect of higher ACRs within that group for renal and nonrenal deaths was maintained.
Random urine ACR is a stable and robust marker of renal disease, which is multideterminant. A broad base of shared risk factors probably explains the simultaneous emergence of the excessive renal and nonrenal chronic disease morbidities from which these populations suffer. Thus, albuminuria is a unifying marker for the harmful effects of the spectrum of chronic disease, and perhaps beyond. Dipstick urine protein is a useful surrogate for ACR when resources are constrained and disease burdens high.
偏远地区的澳大利亚原住民正经历肾病、2型糖尿病、高血压和心血管疾病的流行。成人死亡率增加了3至6倍,肾衰竭增加了20倍以上。肾病以蛋白尿为特征。我们描述了其在北领地两个偏远社区的分布及相关性。
在社区1的观察包括对939名成年参与者(18岁及以上,招募率90%)进行筛查、一个治疗项目以及8至11年的随访。在社区2,对259人(占成年人的60%)进行筛查,检测项目包括糖化血红蛋白、同型半胱氨酸、C反应蛋白(CRP)、巨细胞病毒血清学以及颈动脉内膜中层厚度(CIMT)。采用免疫分析法在随机尿样中检测白蛋白/肌酐比值(ACR),单位为g/mol,微量白蛋白尿定义为3.4至33,显性白蛋白尿定义为ACR 34+。
尿试纸蛋白微量+能正确分类76%的ACR 3.4+人群,尿试纸蛋白1+能正确分类82%的ACR 34+人群。在社区1的部分人群中,ACR在葡萄糖负荷和水利尿情况下保持稳定。ACR水平随年龄急剧上升。社区1中微量和显性白蛋白尿的发生率分别为28%和21%,在社区B中分别为31%和13%。ACR与估计肾小球滤过率(GFR)呈负相关。ACR还与体重、血压、胆固醇、甘油三酯、随机血糖、糖化血红蛋白、同型半胱氨酸和γ-谷氨酰转移酶水平呈正相关,与高密度脂蛋白胆固醇呈负相关。ACR与皮肤溃疡、疥疮、幽门螺杆菌高滴度抗体、巨细胞病毒高滴度抗体、CRP在大幅升高范围内以及出生体重呈负相关。最后,ACR与CIMT相关。基线ACR可预测随时间推移GFR的下降。ACR 3.4+可预测全因和心血管住院情况,而ACR 34+可预测11年内发生的所有肾衰竭、全因自然死亡和心血管疾病死亡。对ACR 34+人群进行血管紧张素转换酶抑制剂(ACEi)治疗可降低肾衰竭和自然死亡,但该组内较高ACR对肾脏和非肾脏死亡的分级效应仍然存在。
随机尿ACR是一种稳定且可靠的肾病标志物,其受多种因素影响。广泛的共同危险因素可能解释了这些人群同时出现过多的肾脏和非肾脏慢性疾病发病率的原因。因此,蛋白尿是一系列慢性疾病有害影响的统一标志物,甚至可能更广泛。当资源有限且疾病负担较高时,尿试纸蛋白是ACR的有用替代指标。